Question-and-Answer Session
Operator
(Operator Instructions). Our first question is from the line of Jason Mills - Canaccord Adams.
Jason Mills - Canaccord Adams
First question is more of a macro question with respect to your markets. Perhaps it would be helpful if you could give your assessment of the growth profile within your three target markets today, the organic growth you’re showing within those target markets, and how long do you expect it to take to get to or surpass market growth in each of those target markets.
Jan Keltjens
Let me give you some high level information. There is a little bit of black signs in reading the market size, but the way we peg the markets and these are global numbers, if you look at our peripheral vascular division, that overall market is growing at about 7%. Within that of course the varicose vein ablation market is growing faster than the average, but the average we think is about 8%. On vascular access, we think it’s about 7%, and interventional oncology or minimal invasive oncology we think it’s about 9-10%, something along those lines. There is a bandwidth nature to those numbers. So actually what you see is if you take our guidance we think that we have a good shot at growing at market rate. I mean it averages out I think I said in my comments about 7-9% or 7-10% if you want to say. That’s actually in line with our guidance. So I don’t think we’re going to incur all that much damage in terms of losing market share, but our ambitions are more far reaching than that.
Jason Mills - Canaccord Adams
Within what timeframe? Should we see the first half of fiscal 2010 lower than those market growth rates and then with new products, you have the Centros in the second half; the second part of my question asked about vascular access, perhaps resolving some of the issues there and filling a product line towards the end of the year and helping the second half. Am I thinking about that right?
Jan Keltjens
Well, I’d be a little cautious. We don’t give quarterly guidance, and there’s a reason for that, so I want to stay away from that a little bit here as well. As I mentioned we have launched four, frankly if you pull in the software release 2.07, we launched 5 products in the past two months or 7-8 weeks. They will help drive some growth. Some of the products will continue to grow of course, and then there’s some other stuff that comes on stream later in the year, but I wouldn’t want to give too much color on whether growth is going to be front loaded or back loaded. I think we should see a fairly stable performance throughout the year, I’d say.
- To read the full transcript on Seeking Alpha, click here »
